Ilaria Conti

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

William D. Tap, Robin L. Jones, Brian A. Van Tine et al. · The Lancet · 2016 · 588 citations

Medicine, Oncology, Pharmacology +9

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem et al. · Annals of Oncology · 2018 · 503 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 309 citations · Full text

Medicine, Cancer Biology, Oncology +16

Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

Shih-Hsun Chen, Youyan Zhang, Robert D. Van Horn et al. · Cancer Discovery · 2016 · 172 citations

Life Sciences, Molecular Biology, Oncology +15

Monocyte/Macrophage-Derived Microparticles Up-Regulate Inflammatory Mediator Synthesis by Human Airway Epithelial Cells

Chiara Cerri, D. Chimenti, Ilaria Conti et al. · The Journal of Immunology · 2006 · 100 citations · Full text

Life Sciences, Cell Biology, Immunology +17